Cardiac Atrophy and Heart Failure In Cancer.
Cardiac Atrophy and Heart Failure In Cancer.
复制标题
DOI：
10.15420/cfr.2017:3:2
复制
发表时间：
2017-04-01
影响因子：
--
通讯作者：
Lyon, Alexander R
中科院分区：
文献类型：
--
作者：
Sweeney, Mark;Yiu, Angela;Lyon, Alexander R
癌症患者心脏的功能变化可能是疾病本身和各种癌症治疗的结果，随着癌症患者生存率的提高，限制心脏损伤已成为一个越来越重要的问题。癌症诱导的心脏萎缩过程可能包括心肌细胞萎缩和凋亡、蛋白质合成减少、自噬增加和通过泛素-蛋白体系统的蛋白水解。除了恶性肿瘤对心脏的直接影响外，已知几种化疗剂会影响心肌，特别是蒽环类药物。本报告的目的是回顾癌症和癌症治疗对心脏的影响，以及对潜在机制的了解。此外，限制和治疗癌症相关的心脏萎缩的临床策略进行了讨论，强调心脏病学家和肿瘤学家的多学科方法的好处，以优化护理模式，改善癌症患者的预后。
Functional changes in the heart in patients with cancer can be a result of both the disease itself and various cancer therapies, and limiting cardiac damage has become an increasingly important issue as survival rates in patients with cancer have improved. Processes involved in cancer-induced cardiac atrophy may include cardiomyocyte atrophy and apoptosis, decreased protein synthesis, increased autophagy and proteolysis via the ubiquitin-proteosome system. Further to direct effects of malignancy on the heart, several chemotherapeutic agents are known to affect the myocardium, in particular the anthracyclines. The aim of this report is to review the effects of cancer and cancer treatment on the heart and what is known about the underlying mechanisms. Furthermore, clinical strategies to limit and treat cancer-associated cardiac atrophy are discussed, emphasising the benefit of a multidisciplinary approach by cardiologists and oncologists to optimise models of care to improve outcomes for patients with cancer.